The overall objective of this project is to study the influence of modern anti-inflammatory treatments in established inflammatory rheumatic diseases (IRD) on immune response elicited by pneumococcal vaccination using 13-valent conjugate vaccine and influenza vaccination. In addition, the aim is to study the clinical aspects of vaccination regarding: tolerability in immunosuppressed patients with IRD, impact on existing rheumatic disease, possible association with onset of new autoimmune diseases, long-term immunity following pneumococcal vaccination, efficacy in preventing invasive pneumococcal diseases and influenza related serious infections. Results from this study are expected to bridge the existing knowledge gap and contribute to body of evidence needed for recommendations and implementation of vaccination program in IRD patients.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
300
Skåne University hospital, Dept of rheumatology
Lund, Sweden
antibody response following vaccination
measurement of antibody levels against different pneumococcal capsular serotypes and 3 influenza virus strains
Time frame: 4-6 weeks after pneumococcal and influenza vaccination
long-term immunity following pneumococcal vaccination
measurement of antibody levels against different pneumococcal capsular serotypes
Time frame: 3 years after pneumococcal vaccination
long-term immunity after vaccination with pneumococcal conjugate vaccine
measurement of antibody levels against different pneumococcal polysaccharide serotypes
Time frame: 5 years after vaccination
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.